731 related articles for article (PubMed ID: 33532796)
1. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
Jangra S; Ye C; Rathnasinghe R; Stadlbauer D; ; Krammer F; Simon V; Martinez-Sobrido L; García-Sastre A; Schotsaert M
medRxiv; 2021 Jan; ():. PubMed ID: 33532796
[TBL] [Abstract][Full Text] [Related]
2. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
3. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
[TBL] [Abstract][Full Text] [Related]
4. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
5. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
6. Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage.
Álvarez-Díaz DA; Laiton-Donato K; Torres-García OA; Ruiz-Moreno HA; Franco-Muñoz C; Beltran MA; Mercado-Reyes M; Rueda MG; Muñoz AL
Virus Res; 2022 Jan; 308():198629. PubMed ID: 34780883
[TBL] [Abstract][Full Text] [Related]
7. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Diamond M; Chen R; Xie X; Case J; Zhang X; VanBlargan L; Liu Y; Liu J; Errico J; Winkler E; Suryadevara N; Tahan S; Turner J; Kim W; Schmitz A; Thapa M; Wang D; Boon A; Pinto D; Presti R; O'Halloran J; Kim A; Deepak P; Fremont D; Corti D; Virgin H; Crowe J; Droit L; Ellebedy A; Shi PY; Gilchuk P
Res Sq; 2021 Feb; ():. PubMed ID: 33594356
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.
Kuzmina A; Khalaila Y; Voloshin O; Keren-Naus A; Boehm-Cohen L; Raviv Y; Shemer-Avni Y; Rosenberg E; Taube R
Cell Host Microbe; 2021 Apr; 29(4):522-528.e2. PubMed ID: 33789085
[TBL] [Abstract][Full Text] [Related]
11. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
[TBL] [Abstract][Full Text] [Related]
12. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
13. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
15. Functional Antibodies Against SARS-CoV-2 Receptor Binding Domain Variants with Mutations N501Y or E484K in Human Milk from COVID-19-Vaccinated, -Recovered, and -Unvaccinated Women.
Demers-Mathieu V; Hakansson AP; Hall S; Lavangnananda S; Fels S; Medo E
Breastfeed Med; 2022 Feb; 17(2):163-172. PubMed ID: 34809492
[No Abstract] [Full Text] [Related]
16. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
[TBL] [Abstract][Full Text] [Related]
18. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
medRxiv; 2021 Aug; ():. PubMed ID: 34100029
[TBL] [Abstract][Full Text] [Related]
19. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
20. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
